drinking alcohol semaglutide reduces binge-like in mice. (A) Does weight loss, diabetes drug

First Generation The first major commercial wave was led by semaglutide-based products

In the EAE model, activated macrophages, monocytes, dendritic cells, as well as apoptotic oligodendrocytes release pathogen-associated molecular pattern or DAMP, like the high mobility group box protein-1 to the extracellular environment, and initiate an inflammatory response characterized by the activation of the inflammasome (Barclay and Shinohara, 2017

Food Funct 2021;12:10184-95

Asia-Pacific is expected to be the fastest growing region in the GLP-1 receptor agonists obesity drugs market during the forecast period due to increasing obesity rates, rising healthcare awareness, and expanding access to advanced diabetes and obesity care Long-acting GLP-1 Receptor Agonists segment dominated the GLP-1 receptor agonists obesity drugs market with a market share of 55.5% in 2024, driven by its superior weight loss efficacy, once-weekly dosing convenience, and broad adoption of drugs such as semaglutide and tirzepatide Report Scope and GLP-1 Receptor Agonists Obesity Drugs Market Segmentation GLP-1 Receptor Agonists Obesity Drugs Market Trends Expansion Beyond Diabetes Through Multi-Indication Approvals A significant and accelerating trend in the global GLP-1 receptor agonists obesity drugs market is the expansion of these therapies beyond type 2 diabetes into broader indications such as chronic obesity, cardiovascular risk reduction, and potentially even conditions such as sleep apnea and nonalcoholic steatohepatitis (NASH)

Its ability to promote weight loss and lower blood pressure can result in reduced hemodynamic stress on the kidneys, contributing to reduced albuminuria and slowing CKD progression (Kanbay et al